

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**November 5, 2008**  
**MINUTES**

**1. Call To Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 5, 2008

**2. Welcome**

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Ed Behling, M.D.

Jody Bollinger, M.D.

Kelly Jones, Pharm.D.

Jim Lindsay, M.D.

Thomas Phillips, R.Ph.

Tan Platt, M.D.

Debbie Tapley, R.Ph.

George E. Vess, Pharm. D.

Harry Wright, M.D.

**DHHS Staff Present:**

Emma Forkner, Medicaid Director

Felicity Myers, Deputy Director

Marion Burton, M.D.

James M Assey, R.Ph.

Mike Blakely, R.Ph.

Deidra Singleton, J.D.

Nikole Boland, J.D.

**Other Representation:**

First Health Services. – Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, August 6, 2008.**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

Ms. Forkner addressed the Committee and thanked them for their continued service. She advised the Committee that Medicaid will be cutting 8.1% from the budget for the current fiscal year.

**B. Public Comment**

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

<b>Company</b>	<b>Speaker</b>	<b>Drug</b>
Gilead Sciences	Ali H Toumadj, PharmD	Viread®
Bristol Myers Squibb	Heidi Googe, PharmD	Baraclude®
Inspire	Keith Reel??	AzaSite

**C. Drug Classes for Review**

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Immunosuppressants
- Androgenic Agents
- Androgen Hormone Inhibitors
- NK1 Antagonist
- Hepatitis B Therapy
- Long Acting Beta Adrenergic Nebulizers
- Ophthalmic Macrolide
- Nitroimidazoles
- NMDA Receptor Antagonist
- Cholinesterase Inhibitors

The chart below represents the recommendations from the P & T Committee:

<i>Immunosuppressants</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
AZASAN® AZATHIOPRINE CELLCEPT® CYCLOSPORINE GENGRAF® IMURAN® MYFORTIC® NEORAL® PROGRAF® RAPAMUNE® SANDIMMUNE®	

<i>Androgenic Agents</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ANDRODERM® ANDROGEL® TESTIM®	

<i>Androgen Hormone Inhibitors</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
AVODART® FINASTERIDE	PROSCAR®

<i>NKI Antagonist</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
EMEND®	

<i>Hepatitis B Therapy</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
BARACLUDE® EPIVIR HBV® HEPSERA® TYZEKA®	

\*Add footnote to posting that Viread® is available without PA

<i>Long Acting Beta Agonist Nebulizers</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
	BROVANA® PERFOROMIST®

<i>Ophthalmic Macrolide</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
	AZASITE®

<i>Nitroimidazoles</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
METRONIDAZOLE	FLAGYL® FLAGYL ER® TINDAMAX

<i>NMDA Receptor Antagonist</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
NAMENDA®	

<i>Cholinesterase Inhibitors</i>	
<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ARICEPT® EXELON® CAPSULES AND SOLUTION GALANTAMINE	ARICEPT ODT® COGNEX® EXELON® PATCH RAZADYNE® RAZADYNE ER®

**5. Old Business**

Mary Roberts presented requested information from the last meeting. Patients on both Glaucoma medications and Anti-diabetic medications. Patients 10 and younger on Nasal Steroids who receive refills.

Dr. Behling complimented DHHS and First Health Services staff members on their work with the PDL and PA process.

Kelly Jones requested feedback from Senator Knotts and Representative Howard regarding the response to their questions at the last meeting.

**6. New Business**

The Committee elected a chairman and a vice chairman. Debbie Tapley, R.Ph. was elected Chairperson and Ed Behling, M.D. was elected Vice-Chairperson.

There was discussion about the move to Managed Care. SC DHHS is reviewing the possibility to carve pharmacy services out of the Managed Care Program.

The next meeting's agenda will likely be informational exchange with no PDL review.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Immunosuppressants
- Androgenic Agents
- Androgen Hormone Inhibitors
- NK1 Antagonist
- Hepatitis B Therapy
- Long Acting Beta Adrenergic Nebulizers
- Ophthalmic Macrolide
- Nitroimidazoles
- NMDA Receptor Antagonist
- Cholinesterase Inhibitors

8. **Closing Comments**

The next meeting will be held on Wednesday, February 4, 2009 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 5:10p.m.